The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection

Ara G. Hovanessian, Jean Paul Briand, Elias A. Said, Josette Svab, Stephane Ferris, Hayet Dali, Sylviane Muller, Claude Desgranges, Bernard Krust

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Caveolin-1 is a scaffolding protein that organizes and concentrates specific ligands within the caveolae membranes. We identified a conserved caveolin-1 binding motif in the HIV-1 transmembrane envelope glycoprotein gp41 and designed several synthetic peptides, referred to as CBD1, corresponding to the consensus caveolin-1 binding domain in gp41. In rabbits, these peptides elicit the production of antibodies that inhibit infection of primary CD4 + T lymphocytes by various primary HIV-1 isolates. Interestingly, gp41 exists as a stable complex with caveolin-1 in HIV-infected cells. Anti-CBD1 peptide antibodies, therefore, might be functional by inhibiting the potential interaction of gp41 with caveolin-1. Because of their capacity to elicit antibodies that inhibit the different clades of HIV-1, CBD1-based peptides may represent a novel synthetic universal B cell epitope vaccine candidate for HIV/AIDS. Moreover, such peptides could also have an application as a therapeutic vaccine since CBD1-specific antibodies are rare in HIV-infected individuals from several geographic origins.

Original languageEnglish
Pages (from-to)617-627
Number of pages11
JournalImmunity
Volume21
Issue number5
DOIs
Publication statusPublished - Nov 2004

Fingerprint

B-Lymphocyte Epitopes
Caveolin 1
Virus Diseases
HIV-1
Glycoproteins
Vaccines
Peptides
Antibodies
HIV
Caveolae
AIDS Vaccines
Antibody Formation
Acquired Immunodeficiency Syndrome
Rabbits
Ligands
T-Lymphocytes
Membranes
Infection
Proteins

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases
  • Immunology

Cite this

The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection. / Hovanessian, Ara G.; Briand, Jean Paul; Said, Elias A.; Svab, Josette; Ferris, Stephane; Dali, Hayet; Muller, Sylviane; Desgranges, Claude; Krust, Bernard.

In: Immunity, Vol. 21, No. 5, 11.2004, p. 617-627.

Research output: Contribution to journalArticle

Hovanessian, AG, Briand, JP, Said, EA, Svab, J, Ferris, S, Dali, H, Muller, S, Desgranges, C & Krust, B 2004, 'The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection', Immunity, vol. 21, no. 5, pp. 617-627. https://doi.org/10.1016/j.immuni.2004.08.015
Hovanessian, Ara G. ; Briand, Jean Paul ; Said, Elias A. ; Svab, Josette ; Ferris, Stephane ; Dali, Hayet ; Muller, Sylviane ; Desgranges, Claude ; Krust, Bernard. / The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection. In: Immunity. 2004 ; Vol. 21, No. 5. pp. 617-627.
@article{59fa5cb0bbba4ca9810f28d062b4a39a,
title = "The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection",
abstract = "Caveolin-1 is a scaffolding protein that organizes and concentrates specific ligands within the caveolae membranes. We identified a conserved caveolin-1 binding motif in the HIV-1 transmembrane envelope glycoprotein gp41 and designed several synthetic peptides, referred to as CBD1, corresponding to the consensus caveolin-1 binding domain in gp41. In rabbits, these peptides elicit the production of antibodies that inhibit infection of primary CD4 + T lymphocytes by various primary HIV-1 isolates. Interestingly, gp41 exists as a stable complex with caveolin-1 in HIV-infected cells. Anti-CBD1 peptide antibodies, therefore, might be functional by inhibiting the potential interaction of gp41 with caveolin-1. Because of their capacity to elicit antibodies that inhibit the different clades of HIV-1, CBD1-based peptides may represent a novel synthetic universal B cell epitope vaccine candidate for HIV/AIDS. Moreover, such peptides could also have an application as a therapeutic vaccine since CBD1-specific antibodies are rare in HIV-infected individuals from several geographic origins.",
author = "Hovanessian, {Ara G.} and Briand, {Jean Paul} and Said, {Elias A.} and Josette Svab and Stephane Ferris and Hayet Dali and Sylviane Muller and Claude Desgranges and Bernard Krust",
year = "2004",
month = "11",
doi = "10.1016/j.immuni.2004.08.015",
language = "English",
volume = "21",
pages = "617--627",
journal = "Immunity",
issn = "1074-7613",
publisher = "Cell Press",
number = "5",

}

TY - JOUR

T1 - The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection

AU - Hovanessian, Ara G.

AU - Briand, Jean Paul

AU - Said, Elias A.

AU - Svab, Josette

AU - Ferris, Stephane

AU - Dali, Hayet

AU - Muller, Sylviane

AU - Desgranges, Claude

AU - Krust, Bernard

PY - 2004/11

Y1 - 2004/11

N2 - Caveolin-1 is a scaffolding protein that organizes and concentrates specific ligands within the caveolae membranes. We identified a conserved caveolin-1 binding motif in the HIV-1 transmembrane envelope glycoprotein gp41 and designed several synthetic peptides, referred to as CBD1, corresponding to the consensus caveolin-1 binding domain in gp41. In rabbits, these peptides elicit the production of antibodies that inhibit infection of primary CD4 + T lymphocytes by various primary HIV-1 isolates. Interestingly, gp41 exists as a stable complex with caveolin-1 in HIV-infected cells. Anti-CBD1 peptide antibodies, therefore, might be functional by inhibiting the potential interaction of gp41 with caveolin-1. Because of their capacity to elicit antibodies that inhibit the different clades of HIV-1, CBD1-based peptides may represent a novel synthetic universal B cell epitope vaccine candidate for HIV/AIDS. Moreover, such peptides could also have an application as a therapeutic vaccine since CBD1-specific antibodies are rare in HIV-infected individuals from several geographic origins.

AB - Caveolin-1 is a scaffolding protein that organizes and concentrates specific ligands within the caveolae membranes. We identified a conserved caveolin-1 binding motif in the HIV-1 transmembrane envelope glycoprotein gp41 and designed several synthetic peptides, referred to as CBD1, corresponding to the consensus caveolin-1 binding domain in gp41. In rabbits, these peptides elicit the production of antibodies that inhibit infection of primary CD4 + T lymphocytes by various primary HIV-1 isolates. Interestingly, gp41 exists as a stable complex with caveolin-1 in HIV-infected cells. Anti-CBD1 peptide antibodies, therefore, might be functional by inhibiting the potential interaction of gp41 with caveolin-1. Because of their capacity to elicit antibodies that inhibit the different clades of HIV-1, CBD1-based peptides may represent a novel synthetic universal B cell epitope vaccine candidate for HIV/AIDS. Moreover, such peptides could also have an application as a therapeutic vaccine since CBD1-specific antibodies are rare in HIV-infected individuals from several geographic origins.

UR - http://www.scopus.com/inward/record.url?scp=8544258110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8544258110&partnerID=8YFLogxK

U2 - 10.1016/j.immuni.2004.08.015

DO - 10.1016/j.immuni.2004.08.015

M3 - Article

C2 - 15539149

AN - SCOPUS:8544258110

VL - 21

SP - 617

EP - 627

JO - Immunity

JF - Immunity

SN - 1074-7613

IS - 5

ER -